Introduction
A double-blind, Phase III clinical trial was designed to study the treatment effect of a single pill combination (SPC) of 80 mg telmisartan and 10 mg amlodipine in lowering systolic blood pressure (SBP). This was an 8-week study with three treatment groups, ie, SPC, telmisartan, and amlodipine. A forced titration schedule for amlodipine was applied, ie, patients who were randomized to amlodipine or to SPC were treated for the first 2 weeks with amlodipine 5 mg, and then titrated to 10 mg of amlodipine for another 6 weeks. A constant dose of 80 mg telmisartan was applied for the entire 8-week treatment period.
After a single-blind washout of 3-4 weeks, a total of 858 subjects with severe hypertension (SBP .180 mmHg) were randomized in a 2:1:1 ratio to the three treatment groups. In total, 421 subjects were randomized to SPC, 217 subjects were randomized to telmisartan, and 220 to amlodipine.
Blood pressure was measured at baseline (immediately before randomization, week 0), and at 1, 2, 4, 6, and 8 weeks post baseline. The primary endpoint was change from baseline in mean SBP (seated trough cuff) following 8 weeks of treatment. The key secondary endpoints were changes from baseline in mean seated trough cuff SBP following 1, 2, 4, and 6 weeks of treatment. In this setting, the interest was that after successfully demonstrating superiority of the SPC over both of its components at study 8 Sha et al termination, the secondary objective was to evaluate at what stage in time such superiority is observed. The secondary objective can be considered as determining the time to onset of drug action. The study design is shown in Figure 1 .
The protocol-specified testing procedure starts with the following primary hypotheses: H 0A : µ S8 $ µ A8 versus H 1A : µ S8 , µ A8 H 0T : µ S8 $ µ T8 versus H 1T : µ S8 , µ T8 where µ S8 is the mean change in SBP from baseline to week 8 in the SPC-treated group, and µ A8 and µ T8 are the respective changes in the amlodipine and telmisartan groups. The primary interest is to demonstrate that the SPC is superior to both of the component drugs after 8 weeks of treatment. Hence, both primary null hypotheses need to be rejected in order to demonstrate the efficacy of the SPC after 8 weeks of treatment and no adjustment for multiple testing is necessary. Because the objective is to show superiority, one-sided hypotheses are used. In Phase III, conventionally the two-sided α type I error is 0.05, and therefore, for these one-sided hypotheses tests, α=0.025 is used in testing each individual hypothesis.
If both of the above primary null hypotheses are rejected, the SPC can be claimed to be superior to both of the component drugs after 8 weeks of treatment and the primary objective of this study is achieved. However, if either one of the primary null hypotheses is not rejected, then further testing is stopped and the SPC cannot be claimed to be superior to both of the component drugs.
If the primary null hypotheses are rejected, then (as prespecified in the protocol) the following sets of key secondary hypotheses are tested:
where µ Si is the mean change in SBP from baseline to week i in the SPC-treated group, µ Ai and µ Ti are the respective changes in the amlodipine and telmisartan groups; i = 6, 4, 2, and 1.
First, testing of the key secondary hypotheses at week 6 was planned. Again, if both respective null hypotheses can be rejected, superiority of the SPC after 6 weeks of treatment is demonstrated. This testing procedure continues to week 4, week 2, and week 1 in a stepwise sequence until either all the secondary null hypotheses (at week 6, week 4, week 2, and week 1) are all rejected (each at the one-tailed significance level of 0.025) or until at least one null hypothesis is not rejected. This follows a gatekeeping procedure and hence no alpha adjustment is necessary.
Statistical considerations
Longitudinal datasets are almost never complete and the analyst has to cope with missing data.
1 Traditionally, such datasets following patients over time were analyzed using last observation carry forward (LOCF) methodology in most of the Phase III clinical trials. The advantages of LOCF include: it implements the intent-to-treat principle; it satisfies the one-patient, one-vote approach; and it is easy to understand Notes: *low-dose telmisartan/amlodipine and low-dose amlodipine indicate that patients were randomized to SPc or to the amlodipine group and received 5 mg of amlodipine during the first 2 weeks. This is a double-blind study. After a 3-4-week single-blind run-in period, patients are randomized to 8 weeks of double-blind treatment in a 2:1:1 ratio. 4 This Phase III antihypertensive study comparing the SPC of telmisartan and amlodipine with its monocomponents was conducted in 2008/2009 and the prespecified primary analytical model was MMRM in the protocol. Based on the study protocol, the proposed sensitivity analysis of the primary endpoint was LOCF.
The dataset for this study is interesting for three reasons: the timing of this study is around the time when the pharmaceutical industry and regulatory agencies are evolving statistical analysis from LOCF to MMRM; with an 8-week design and five time points for analysis, this study offers enough flexibility for consideration of a wide variety of statistical models; and the nature of this study requires analysis of each time point in a sequential fashion (week 8, then week 6, then week 4, then week 2, and finally week 1). Furthermore, clinical scientists have plenty of experience with antihypertensives, as blood pressure is a well established clinical endpoint, and it is a continuous measure (with normal distribution) where both LOCF and MMRM can readily be applied for data analysis. With over 800 patients recruited for this study, model convergence is not likely to be an issue. The results of the study are summarized in Figure 2 .
The next section provides the primary analysis results based on MMRM, including the sensitivity analysis (LOCF) for the primary endpoint. This is followed by two sections describing alternative analyses. Finally a discussion is presented.
Primary analysis and sensitivity analyses
The prespecified primary analysis is based on an MMRM model, where the response is SBP change from baseline to week 8. Fixed effects include treatment, week, and treatment by week interaction. Baseline SBP is used as a fixed continuous covariate, and the baseline by week interaction is also included as a fixed effect. In this model, the patient is considered as a random effect, and an unstructured variance/covariance matrix is used for this random effect. 
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Linear mixed models have appeared extensively in the literature. We summarize some pertinent results below for convenience. Let i = 1, 2, … N index the number of subjects in a study, and let y i be the column vector of observations made on the i-th subject. The dimensions of y i , denoted by n i , may be different across individuals, either by design or due to missing values. We consider a general linear mixed model of the form
where β is a column vector of fixed effects, X i is a design (incidence) matrix relating the observations of the i-th subject to β, b i is a column vector of random effects, Z i is a design (incidence) matrix relating the observations of the i-th subject to b i , and ε i is a column vector of random errors. Assuming b i and ε i are independently distributed with zero mean and variancecovariance matrices, G and R i , respectively, we have
The primary model includes five time points, ie, changes in SBP from baseline to weeks 1, 2, 4, 6, and 8. The variancecovariance matrix G was modeled as unstructured (UN). The SAS code of the primary model is given below: proc mixed data=dta1235; class ptno atr nomwk; model syschg= a t r n o m w k a t r * n o m w k b s y s s e bsysse*nomwk/ddfm=kr s; repeated nomwk/subject=ptno type=un r; lsmeans atr*nomwk/pdiff cl; run;
Note that two models were used in the clinical trial report for this study; one is the low-dose model, which includes responses up to weeks 1 and 2 and the other is a high-dose model that includes responses up to weeks 4, 6, and 8. In this paper, all these time points are included in a single model. The analytical results are summarized in Table 1 .
Based on these results, it is clear that the SPC is significantly different from both of the component drugs at week 8 (P,0.0001 for the comparison of SPC against telmisartan and P=0.0002 for the SPC against amlodipine). Following the prespecified sequence of secondary endpoints, both null hypotheses (SPC compared with telmisartan and SPC compared with amlodipine) are rejected for week 8, week 6, week 4, week 2, and week 1: P-values for week 6 are ,0.0001 and 0.0001; P-values for week 4 are ,0.0001 and 0.0001; P-values for week 2 are ,0.0001 and 0.0001; and finally, for week 1, the P-values are ,0.0001 and 0.0070, respectively. Therefore, the primary analysis for the primary and secondary endpoints indicates that the SPC is superior to both of the component drugs across all time points (week 8, week 6, week 4, week 2 and week 1). In other words, the superiority of SPC against the individual component of either telmisartan or amlodipine started at week 1, and the separation continues throughout the entire 8 weeks.
For the primary endpoint (change in SBP at week 8) and the secondary endpoints, the sensitivity analysis is also performed, ie, LOCF up to weeks 8, 6, 4, 2, and 1. In these analyses, there are only two fixed effects, ie, the treatment effect and the continuous baseline covariate. Hence an analysis of covariance is performed to compare the treatment effect at weeks 8, 6, 4, 2, and 1 using the LOCF data. Note that when all of the post-baseline measurements are missing, the baseline is not carried forward.
From Table 2 , the statistical significance at week 8 is detected when SPC is compared with telmisartan (P,0.0001) 
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Single pill combination of telmisartan and amlodipine and with amlodipine (P,0.0001). These significant findings continue from week 8 down to week 6 (P-values are ,0.0001 and 0.0002), week 4 (P-values are ,0.0001 and 0.0002), week 2 (P-values are ,0.0001 and 0.0002), and week 1 (P-values are ,0.0001 and 0.0064). Results of these sensitivity analyses further support the primary analyses of both the primary and the secondary endpoints, indicating that SPC is superior to both of the component drugs at the primary time point (week 8), as well as the secondary time points (weeks 6, 4, 2, and 1) in treating patients with severe hypertension. Further, these comparisons are robust with respect to different data analysis models.
Alternative analysis: hybrid model considering time as continuous in random effect
One of the potential problems in implementing MMRM models is that when there are too many time points and without a large sample size, an unstructured covariance matrix may not be estimable. For example, in a study with a duration of 12 months designed with monthly visits (12 time points after baseline), the unstructured covariance matrix contains 78 (=12 * 13/2) parameters to be estimated.
In practice, there can be missing data at various time points, and this may result in the MMRM algorithm not being able to converge. Typically under this situation, statisticians tend to choose a simpler covariance structure, such as compound symmetry or autoregressive of order 1, both of which require a smaller number of parameters to be estimated. However, these simpler covariance structures may not be justified by the data. When there are many time points and a compound symmetry covariance structure is assumed, it is questionable to assume that "the correlation between two neighboring time points is the same as the correlation between two time points that are very far apart." In most of the therapeutic areas, such an assumption may not hold. Regarding the autoregressive covariance structure, although it may be appropriate in a design with equal time spacing, there can be problems under a general setting, in that correlations decay to zero fairly rapidly. One proposal to balance the two problems, ie, not too many parameters in the covariance matrix and without very strong assumptions of correlation structure, is to assume a hybrid model. In this proposal, time is considered as discrete in the fixed effect, and then in modeling the random effect, time is considered as continuous. In such a hybrid model, the random effect can be expressed in terms of the covariance matrix G. In most of the clinical trial applications, the interest is on marginal means and their differences between treatment groups at a particular visit (eg, the treatment difference at week 8, µ F8 − µ T8 in the antihypertensive study comparing the SPC with its component drugs). The random effects are mainly used as a device to model the covariances among repeated measures within a subject.
Under this setting, there are only four parameters that need to be estimated for the random effect: g 11 , g 12 , g 22 , and the residual σ 2 . This proposed alternative is more realistic and is practical because time is considered as continuous in the random effect, which reflects actual clinical practice. It is also invariant with respect to specification of time units. An analysis of the results using the proposed hybrid model is shown below. Details of the analysis, together with SAS code and SAS output, can be found in the Supplementary material.
In this analysis, a hybrid MMRM using discrete time as a fixed effect with a random slope (continuous time for the random effect) is fitted with the seated SBP observed post baseline. One advantage of this model is that the number of parameters associated with the random effect is reduced to only four, ie, g 11 , g 12 , g 22 22 For covariance at weeks 4 and 6 in the same subject, the estimate is 146.69 + 4 (−5.6517) + 6 (−5.6517) + (4) (6) (1.5136) = 126.4994.
The primary analysis for this antihypertensive trial is based on the PhRMA recommendation, 2 where the covariance matrix is modeled as unstructured. In this hybrid model, the covariance estimates are closer to the PhRMA model (used in the primary analysis) than to the compound symmetry (see Table 3 ). Under the compound symmetry model, three parameters are used for covariance estimates, while the hybrid model uses only one more. In the case where many time points are included in a trial, this hybrid model can be a reasonable alternative for consideration.
Interpretation of fixed effects is similar to that of the primary model (unstructured covariance matrix). Note that for the week 8 treatment effect, the SPC estimate is −47.5, the SPC-T80 difference is −10.6, and the SPC-A10 difference is −4.4. These estimates are almost identical (differences are in further digits after the decimal point) to the PhRMA model estimates. This alternative analysis using a hybrid model reached the same conclusion as the primary model. However, when comparing the t-values with the primary model (8.95 for T80-SPC and 3.71 for A10-SPC), the hybrid model seems to be less powerful.
For analysis of secondary endpoints, the hybrid model was applied to weeks 6 and 4 separately (although the SAS code in the supplement does not reflect this). Note that in the week 6 analysis, only data from weeks 1 to 6 were included, ie, week 8 data were excluded from the model. Similarly, in the week 4 hybrid model analysis, data obtained from time points after week 4 were excluded. The results are shown in Table 4 Note that in a simpler model with only two time points 
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Single pill combination of telmisartan and amlodipine (eg, weeks 1 and 2), the covariance matrix obtained from the hybrid model employs the same number of parameters as those from unstructured covariance. Therefore, a separate hybrid model for weeks 2 and 1 was not performed. Results from weeks 6 and 4 of the hybrid model demonstrate statistical significance of the SPC against each of the component drugs both at weeks 6 and 4 (P-values for week 6 are ,0.0001 and 0.0002; P-values for week 4 are ,0.0001 and 0.0002).
Results for weeks 2 and 1 can be obtained from the primary MMRM model, and are hence found in Table 1 .
The analysis results obtained from the hybrid model further support the conclusions from the primary MMRM model. This is consistent for the primary endpoint, and across all the secondary endpoints.
Alternative analysis: grouping method
In addition to typical LOCF analysis, MMRM, and the hybrid model, many other approaches can be applied to longitudinal data analysis. In the classification of missing data mechanisms, missing not at random (MNAR) can be further broken down into two subcategories, ie, nonignorable outcome-based dropout which depends directly on observed and unobserved outcome, and nonignorable randomcoefficient-based dropout which depends indirectly on the outcomes through random coefficients. 5 From a frequentist statistician's perspective, as pointed out by Tipa et al, 6 nonignorable random-coefficient-based dropout can be viewed as one type of nonignorable outcome-based dropout. In the setting of nonignorable random-coefficient-based dropout, Park et al 7 proposed an asymptotically unbiased estimate of the overall treatment effect. Remarkably, one substantial advantage of their method lies in the fact that there is no requirement of any specified missing data model. Hence this advantage can be used to address some controversial issues that some other methods may have, such as misspecification of dropout model. Additionally, more flexibility is available and generally appreciated, especially in clinical trials where a detailed statistical analysis plan must be fully specified before the treatment information is unblinded. Briefly, the idea of the grouping method is to group the patients into K subgroups depending on the total number of observed time points. Kong et al 8 take this grouping approach and further broaden the treatment effects by using a saturated time effect model proposed by Wei and Shih. 9 The resulting model provides an unbiased estimator for treatment effect at time t k . Here we will describe and then apply the method of Kong et al 8 to the same antihypertension study. Without loss of generality, this approach readily applies to most of the longitudinal studies we commonly see. For better presentation of this approach, we first set up the notation of the model framework and then point out the difference from model 1. Let y ij be the j-th component of y i in (1), which denotes the efficacy endpoint of interest measured from the i-th patient at visit time t j for i = 1, …, n and j = 1, …, K. The primary endpoint of this study, however, is the measurement at last visit t k . Similar to model (1), y ij is assumed to follows a linear mixed effects model,
for i = 1, …, n and j = 1, …, K. For the i-th patient, X i is a p-dimensional vector which usually represents the baseline characteristics and treatment indicator; Z i is a q-dimensional vector associated with the subject level random effect b i , which is assumed to follow a multivariate normal distribution N q (0, V). One exception is noted in the coefficient of X i , denoted by β j , which is no longer assumed to be constant over time. Compared with model 1, the major difference is that a random coefficient-based nonignorable dropout model is assumed, ie, the dropout probability for patient i is assumed to be an unspecified function of X i and random coefficient b i .
To estimate the treatment effect at time t k , a least squares estimator based on the patients who remain in the study at time t k can be written as where R K denotes the set of patients who remain in the study at time t K . However, this estimator is not unbiased due to dropout at certain previous time t j , for any j , K. In order to construct an unbiased estimator, Kong et al This has been shown by Kong et al 8 to be unbiased and also consistent for is β k .
Next, we apply this model [2] to analyze this antihypertensive trial, and the results of comparing each component drug with the SPC are summarized in Table 5 . R software version 2.15.1 10 was used. Results for the primary and secondary endpoints are also summarized in Table 5 . As seen in this table, analysis of the primary endpoint shows that at week 8, the treatment effect of the SPC subtracting the T80 group is −11.1, and the SPC subtracting the A10 group is −4.6. These estimates are close to the MMRM estimates (ie, SPC-T80 is −10.6 and SPC-A10 is −4.4). For this dataset, in order to compare the power of the Kong et al model with the primary model, we can check the test statistic, ie, the t-value or z-value in the output. As a result, the primary model yields 8.95 for SPC-T80, and 3.71 for SPC-A10, whereas the Kong et al model [2] provides 8.41 and 3.83, respectively. The power of model [2] seems to be comparable with the primary MMRM model in this antihypertensive trial. Comparisons at week 8 indicate that the benefit of SPC is statistically significant over each of the component drugs.
For analysis of secondary endpoints, the grouping method was applied to weeks 6, 4, and 2. Subsequent measurements beyond the specified visit have been excluded similarly, as described in the analysis using the hybrid model. For instance, in the week 6 analysis, only data from weeks 1 through 6 were included. Note that for week 1, the results obtained from either the primary analysis model or from LOCF should be sufficient. Therefore, week 1 analysis of the grouping method was not performed. The results in Table 5 from weeks 6, 4, and 2 are highly statistically significant, as similarly established in the primary analysis as well as the one using the hybrid model. This reconfirms the superiority of SPC against each of its components.
Discussion
In longitudinal clinical trials, missing data caused by patient dropout often makes it difficult to draw definitive conclusions. In order to minimize this problem in Phase III studies, many important considerations are implemented in the design and trial conduct stage. Once the study is completed and the database is locked, there is not much that can be done to bring the missing data back into the trial. The primary statistical analyses will be performed on the locked database to help formulate the study conclusion. At this stage, in order to demonstrate the robustness of the conclusion, various sensitivity analyses would be performed to see if the primary conclusion can be affected by missing data.
A Phase III antihypertensive clinical trial is introduced in this paper. The objective of this trial is to demonstrate superiority of the treatment effect from an SPC comparing against each component drug. The SPC is a combination of telmisartan 80 mg plus amlodipine 10 mg and the trial was designed to demonstrate that the SPC is superior to both telmisartan and amlodipine. In this 8-week study, the primary endpoint is change from baseline in SBP up to week 8. Secondary endpoints are changes in SBP from baseline up to weeks 6, 4, 2, and 1.
In dealing with missing data, in the past the most frequently used method in the primary statistical analysis of a longitudinal trial was LOCF. However, since publication of the paper by Mallinckrodt et al 2 in 2008, many clinical statisticians have used MMRM to handle the missing data problem. In analyzing the SBP data from this Phase III antihypertensive trial, we prespecified MMRM as the primary model, together with LOCF for sensitivity analysis. The primary analysis is based on two prespecified models: the high-dose model that uses responses at weeks 4, 6, and 8, where the week 8 response is the primary time point, and the low-dose model that uses only weeks 1 and 2 data as responses. In both models, fixed effects include treatment, week, and treatment by week interaction. Baseline SBP is used as a fixed continuous covariate, and the baseline by week interaction is included as a fixed effect. Random effect includes patient effect and residual. The patient effect over time is modeled with an unstructured variance/covariance matrix. In this paper, two alternative analytical methods are introduced, ie, a hybrid MMRM using time as a continuous variable in the random effect (while maintaining time as a discrete variable in the fixed effect) and a grouping method. Statistical analyses were applied to this set of SBP data including the prespecified MMRM, the LOCF sensitivity analyses, as well as these alternative analyses. All analytical results demonstrate a consistent conclusion that the telmisartan plus amlodipine SPC is significantly superior to both of the monotherapies in patients with severe hypertension starting from week 1 post randomization, and throughout the entire 8 weeks of double-blind treatment. For this set of SBP data, the clinical conclusion is robust, regardless of the model choices used for statistical analysis. 
